Full-Time

Director Medical Writing

Dyne Therapeutics

Dyne Therapeutics

201-500 employees

Develops muscle-disease therapies using FORCE platform

Compensation Overview

$190k - $235k/yr

Waltham, MA, USA

Remote

Category
Content & Writing (2)
,
Required Skills
Sharepoint
Data Analysis

Get referred to Dyne Therapeutics

Find people who can refer or advise you

Requirements
  • Bachelor’s degree in life sciences or a related discipline required; advanced degree preferred, with a strong understanding of biochemistry and molecular biology principles
  • 10+ years of medical writing experience in the pharmaceutical or biotechnology industry, with significant experience preparing clinical and regulatory documents
  • Deep experience authoring and reviewing clinical and regulatory documents
  • Ability to lead strategic discussions that align content and messaging across submissions
  • Exceptional communication skills to influence cross-functional stakeholders.
  • Experience overseeing internal and external medical writing resources, including vendors, consultants, and cross-functional contributors
  • Demonstrated expertise writing, editing, and reviewing protocols, clinical study reports, investigator brochures, CTD modules, and other clinical regulatory documents
  • Strong understanding of FDA and international regulations, ICH guidelines, and regulatory processes related to document preparation, production, and submission, including CTD requirements
  • Experience developing and executing medical writing strategy across programs, submissions, or therapeutic areas
  • Proficiency with Microsoft Office, Adobe Acrobat, and shared document management systems such as SharePoint
  • Highly organized, with the ability to prioritize, manage multiple projects simultaneously, and deliver high-quality work under tight timelines
  • Detailed knowledge of requirements for key clinical, nonclinical, and regulatory documents supporting INDs, CTAs, annual reports, and related submissions
  • Strong attention to detail, accuracy, and consistency
  • Ability to synthesize, analyze, and present complex clinical and scientific data clearly and accurately
  • Self-directed, proactive, and effective at problem solving in a fast-paced, cross-functional environment
  • Strong collaboration skills, with the ability to integrate input from multiple contributors into clear, cohesive, submission-ready documents
Responsibilities
  • Lead the planning, authoring, review, and completion of clinical and regulatory documents required for submissions to the FDA and other global health authorities
  • Manage internal and external medical writing resources to deliver accurate, high-quality documents on time and in accordance with established standards
  • Author, edit, and collaborate with cross-functional team members on key documents, including protocols, investigator brochures, clinical study reports, CTD modules, briefing books, and related submission materials
  • Review and refine documents or document sections prepared by functional contributors to ensure quality, consistency, scientific accuracy, and adherence to company and regulatory standards
  • Contribute to project planning and cross-functional working groups to support efficient development, review, approval, and finalization of submission-ready documents
  • Establish and continuously improve medical writing processes, templates, and best practices to increase quality, consistency, and operational efficiency

Dyne Therapeutics develops therapies for serious muscle diseases using its FORCE™ platform, which helps deliver oligonucleotide medicines to muscle tissue. Through a portfolio of experimental therapies, the company advances them in clinical trials (ACHIEVE and DELIVER) with the aim of treating rare muscle diseases. The product works by enhancing targeted delivery of oligonucleotides to muscle, enabling existing genetic medicines to reach affected tissues more effectively. Dyne differentiates itself by its proprietary FORCE™ technology and its focus on rare muscle diseases, positioning itself for growth as trials progress toward potential commercialization. The company’s goal is to bring effective treatments to patients and families affected by serious muscle diseases, expanding options as its therapies advance through development and, potentially, regulatory approval.

Company Size

201-500

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

2017

Get referred to Dyne Therapeutics

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Preclinical data shows sustained dystrophin expression and muscle function improvement after single low dose[1].
  • ACHIEVE trial shows dose-dependent splicing correction and functional improvement in DM1 patients[3].
  • Dyne secured $400M debt facility to support US launches of DMD and DM1 therapies within two years[3]

What critics are saying

  • Sarepta's upadacersen dominates DMD market with 80% adoption, blocking Dyne's switch opportunities in 12–18 months
  • FDA rejection risk for accelerated approval due to inadequate Phase 1/2 data persists in 6–12 months
  • Dyne faces insolvency within 12 months if FDA denies approval due to $200M debt and equity dilution

What makes Dyne Therapeutics unique

  • Dyne's FORCE™ platform targets TfR-1 for precise oligonucleotide delivery to muscle and CNS[1][2].
  • Dyne pioneers low-dose, infrequent therapy for DM1 using FORCE™ platform validation[4][6].
  • Dyne advances clinical programs for DMD and DM1 with fast track and orphan drug designations[3].

Help us improve and share your feedback! Did you find this helpful?

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

0%

2 year growth

-3%
Dyne Therapeutics
Dec 10th, 2025
Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock | Dyne Therapeutics, Inc.

(Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the pricing of an upsized underwritten public offering of 18,980,478 shares of its common stock at a public offering price of $18.44 per share.